Por: MarketWatch Business February 15, 2023
While the ultimate size of the planned bond deal has yet to be determined, proceeds would be used by Amgen to help fund the acquisition with longer-term debt, plus pay fees related to the acquisition, according to a public document filed Tuesday with the U.S. Securities and Exchange Commission. “As reported, we are currently conducting fixed-income investor calls in connection with our financing of the Horizon acquisition,” an Amgen... + full article
MarketWatch USA Business February 15, 2023
While the ultimate size of the planned bond deal has yet to be determined, proceeds would be used by Amgen to help fund the acquisition with longer-term debt, plus pay fees related to the acquisition, according to a public document filed Tuesday with the U.S. Securities and... + más
Amgen to buy Horizon Therapeutics in $26.4B deal | Associated Press
Amgen to buy Horizon Therapeutics in $26.4B deal | 10 WBNS
Fox Business USA Business January 14, 2023
Check out what's clicking on FoxBusiness.com Investors learned of Amgen Inc.’s PLC in December. But a clue to a potential deal emerged months earlier, when insiders in the target company stopped selling stock. The halt to stock sales by executives and directors at Horizon... + más
Turkey stock: Easy, economical way to use more of the bird | Associated Press
Top 10 Most Shorted Stocks List For October 2022 | Forbes
Associated Press USA Business December 12, 2022
Amgen is spending more than $26 billion to dive deeper into rare disease treatments with a deal for drugmaker Horizon Therapeutics. The biotech drug developer said Monday that it will pay $116.50 in cash for each share of Horizon, which makes a thyroid eye disease treatment that... + más
Amgen to buy Horizon Therapeutics in $26.4B deal | ABC News
Fox Business USA Business December 12, 2022
Graviton Biopharmaceutical Holdings Chairman and CEO Sam Waksal discusses growth investment opportunities in biotech and how the sector should be a national priority. Amgen announced on Monday that it will acquire Horizon Therapeutics in a $26 billion deal, extending the... + más
ABC News USA Health December 12, 2022
Amgen is spending more than $26 billion to dive deeper into rare disease treatments with the acquisition of drugmaker Horizon Therapeutics. The biotech drug developer said Monday that it will pay $116.50 in cash for each share of Horizon, which makes a treatment for thyroid eye... + más
10 WBNS USA Health December 12, 2022
LOS ANGELES — Amgen will acquire Horizon Therapeutics, a biopharmaceutical company that focuses on treatments for rare, autoimmune diseases, for about $26.4 billion. Each Horizon shareholder will receive $116.50 per share for each share they own. The deal has an enterprise... + más
Los Angeles Times USA Science December 12, 2022
About iurex | Privacy Policy | Disclaimer |